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INTERNATIONAL ARBITRAGE OF CONTROVERSIAL MEDICAL
TECHNOLOGIES: AN INTRODUCTION
Hiram E. Chodosht
James R. Lisher IPt
During the 2002-2003 academic year, the Case Western Reserve
University Journal of International Law (the "Journal") and the Frederick
K. Cox International Law Center (the "Cox Center") invited a series of
experts to explore the difficulties in global regulation of new bio-medical
technologies. We entitled the symposium International Arbitrage of
Controversial Medical Technologies in order to capture the intersection of
two significant developments.
First, we endeavored to investigate the rapid proliferation of bio-
medical technologies that create deep moral and ethical dilemmas for
lawmakers, e.g., genetic engineering, germ line gene therapy, somatic cell
gene therapy, untested, risky pharmaceuticals for terrible illnesses, and even
biological weapons, and the diverse national approaches to regulating such
activity. Such approaches vary widely: from laissez-faire, market-oriented
self-regulation' in South Korea;2 to strong regulation by states (e.g. the
United Kingdom and Sweden) 3 that endeavor simultaneously to maximize
benefits and minimizing risks;4 to absolute bans (e.g., in France and
Germany) based on the view that some medical technologies (e.g., cloning)
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1 See generally Arthur Caplan, If Science Becomes Politicized, Where Do We Go For
Truth, THE PHILADELPHIA INQUIRER, Sept. 23, 2002 (asserting that politicians should not set
the standards for new biotechnologies; rather, if policy is needed it should be created by
panels that are not accountable to the political party in power).
2 B.J. Lee, Cloning College: South Korea's Biomedical Researchers, Unhampered by
Politics, Do World-Class Research on the Cheap, NEWSWEEK INTERNATIONAL, Mar. 1, 2004,
available at 2004 WL 65299408.
3 See Human Reproductive Act of 2001 c. 23 § 1 et. seq. (2001) (U.K.) (United Kingdom
national law allowing cloning of human embryos for medical and therapeutic purposes); See
also Sweden Backs Research Into Therapeutic Cloning, AGENCE FRANCE PRESSE, Mar. 25,
2004, available at 2004 WL 74002656 (stating that new law would allow therapeutic
research on early stage human embryos, but not on embryos for reproductive research)
4 See Sarah Kate Templeton, Clone Ban Will Not Last, THE SUNDAY HERALD July 28,
2002. at 11.
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should be banned for moral or ethical reasons.5 Absent any overarching
global regime, each national community (from England 6 to Australia 7) must
choose a particular approach somewhere along this regulatory spectrum in
order to answer the troubling questions posed by each controversial
technology.
Second, and in relation to myriad national differences, we
wondered whether the decisions of any one national community could be
easily circumvented. Bio-medical researchers and enterprises and their
activities are not hermetically and unalterably sealed into any one national
jurisdiction. The increasingly primed channels of global exchange
(commerce, technology, information, finance, migration) make it
increasingly easy for those potentially subject to bans or regulations in one
place of operation to choose another, more favorable, less constraining
venue. The combination of primarily national (and divergent) decision-
making and the ease of cross-border transfer give rise to a process of
international legal arbitrage.
A concept derived from the context of securities and commodities
exchange, legal arbitrage is an emerging concept of scholarly
investigation.8 Arbitrage is "the simultaneous purchase in one market and
sale in another of a security or commodity in hope of making a profit on
price differences in the differing markets." 9 This allows an investor to
make a profit by exploiting the differences in price from one market to
another. Legal arbitrage is a variant of the economic practice: those
subject to the law of any one national jurisdiction may alter the location of
their activities in order to take advantage of the legal difference.
5 See George J. Annas, Human Cloning: A Choice or an Echo?, 23 U. DAYTON L. REV.
247, 249-250 (1998) (explaining the problem with cloning, by stating, "The danger is that
through human cloning we will lose something vital to out humanity, the uniqueness of
every human. Cloning a human is also uniquely disturbing because it is the manufacture of
a person made to order, it represents the potential loss of individuality and freedom, and
symbolizes science's unrestrained quest for mastery over nature for the sake of knowledge,
power, and profits.")
6 Steve Connor, Cloned Human Embryo in Britain by End of This Year, THE
INDEPENDENT, May 8, 2004, available at 2004 WL 78362376 (reporting that group of
researchers at Newcastle University have applied for a license, likely to be approved, to
create the first cloned human embryo for the purpose of cloning stem cells).
7 Deborah Smith, Stem-Cell Extraction Becomes a Reality, THE SYDNEY MORNING
HERALD, Apr. 17, 2004, available at 2004 WL 74952802 (reporting that Australia has just
issued its first license to extract stem cells from excess IVF embryos).
8 See, e.g., Pamuela Samuelson, Intellectual Property Arbitrage: How Foreign Rules Can
Affect Domestic Relations,71 U. CHI. L. REv. 223 (2004); Douglas M. Branson, The Very
Uncertain Prospect of "Global" Convergence in Corporate Governance, 34 CORNELL INT'L
L. J. 321, 358 (2001).
9 BLACK'S LAW DICTIONARY 95 (5th ed. 1979).
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Theoretically, arbitrage decisions may be made on the substantive law (or
lack thereof) or the strength (or weakness) of the institutions responsible for
enforcing it. Furthermore, legal arbitrage does not necessarily imply the
choice of weaker legal regimes-the so-called race to the bottom-for two
reasons. First, private researchers or enterprises may choose to operate in
an environment that provides greater legal protection, for example, through
strong patent law. Second, arbitrage decisions are complex; they involve
more than one applicable legal regime (e.g., intellectual property, drug
regulation, labor and employment law, etc.) and also involve non-legal
arbitrage decision-making based on the quality of the telecommunications
infrastructure, the labor force, the financial system, etc. Finally, the
concept of international legal arbitrage involves public as well as private
decision-making. National systems may increasingly make regulatory
decisions in anticipation of these private choices.' For example, South
Korea appears to have provided an attractive environment for labs and
researchers who would be under more invasive scrutiny in the U.S. and
Europe, where they are "hamstrung by political backlash."" The country
has thus attempted strategically to meet the demand for bio-medical
research banned in other countries.1 2 Seoul National University's campus is
now home to several world-renowned scientists and boasts of the highest
in-vitro fertilization success rate in the world.
13
International legal arbitrage may be easier to grasp theoretically than
to document empirically. A number of notorious cases, however, invite
further attention. For example, in 1996 Pfizer used an experimental drug,
Trovan, to treat close to a hundred children with spinal meningitis in
Nigeria.14 The drug had never been tested on children before. Six weeks
later, Pfizer left and shortly thereafter, "locals began reporting severe health
problems, including death, resulting from their involvement with Pfizer's
research."'15 Or take the unverified claims that Clonaid researchers helped a
Florida woman birth to a cloned child dubbed "Eve." Rumors that the
mother had returned to Florida gave rise to a lawsuit against her, which was
10 For a recent exposition of the multiple strategies available to national legal systems to
regulate increasingly global activity, see Hiram E. Chodosh, Globalizing the U.S. Law
Curriculum: The Saja Paradigm, 37 U.C. DAVIS L. REv. 843, 853-859 (2004) (outlining the
strategies states may employ to address cross-border arbitrage problems, e.g., restrictions on
cross-border transfer, extraterritoriality, comparative law reform, public international law,
and international institutions).




14 David Carr, Pfizer's Epidemic: A Need for International Regulation of Human
Experimentation in Developing Countries, 35 CASE J. INT'L L. 15 (2003).
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later dismissed.16 Clonaid also claimed to have helped a patient from The
Netherlands, where cloning is banned. The Dutch patient announced that
she had given birth to the second cloned baby on January 4, 2003.7
Similarly, the emergence of genetic engineering for athletes, "designer
babies," ' germ line therapy,' 9 or new classes of people, coined Genobiliy
2 °
or GenRich2' each simultaneously raise significant arbitrage opportunities
and problems. Strong regulation in one place may push research to more
weakly regulated venues, and some countries may seek to take advantage of
the arbitrage process.22 China has persuaded numerous Western-educated
scientists "to return to a homeland where research on human embryos is
lavishly funded at dozens of laboratories. 23 Singapore recently completed
a new biotech complex called "Biopolis" that has attracted a British Nobel
laureate, a researcher from the group that cloned Dolly the sheep, and an
entire division from the medical school at Johns Hopkins.24 These are
among the many reports of international legal arbitrage of controversial
medical technologies that demand greater attention.
With these interests in mind, and with the guidance of Professor Max
Mehiman, Director of the school's Law-Medicine Center, the Cox Center
and the Journal have committed themselves to continuing this collaborative
research. As a first phase in pursuit of this long-term commitment, we
invited three world-class experts, Dr. Arthur Caplan, 25 Bartha-Maria
16 CNN, Rael: No DNA test for baby Eve, Jan. 3, 2003, available at
http://www.cnn.com/2003/HEALTH/01/03/clone.claims/indez.htinl.
17 See Toby Sterling, Sec Claims It's Clone Another Human, ASSOCIATED PRESS,
available at http:// customwire.ap.org/dynamic/stories/N/NETHERLANDSHUMAN_
CLONING?SITE=INSHE&SECTION=HOME.
18 See Caroline S. Wagner, The Weapons of Mass Creation: Are We Ready for Genetically
Enhanced 'Designer People'? If So, Who Will Make the Titanic Decisions Involved?, L.A.
TIMES, Feb. 13, 2003, available at 2003 WL 2386264.
19 Lee Silver, The God Effect: America 's Religious Conservatives Are Not the Only Ones
who Object to Science on Spiritual Grounds-so do Europe's Greens. The Big Winner is
Asia, NEWSWEEK INTERNATIONAL, Apr. 5, 2004, available at 2004 WL 65299497. See also
George Annas, Resolved: GLGT Should be Prohibited, Remarks at the Case Western
Reserve University Law-Medicine Center 50th Anniversary debate, (Oct. 8, 2003).
20 Maxwell J. Mehiman, The Law Above Averages: Leveling the New Genetic
Enhancement Playing Field, 85 IOWA L. REv. 517, 533 (2000).




25 Arthur L. Caplan has been the director of the Center for Bioethics and Trustee Professor
of Bioethics at the University of Pennsylvania since 1994. He is currently chairman of the
Advisory Committee to the Department of Health and Human Services, Centers for Disease
Control and Food and Drug Administration on Blood Safety and Availability.
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26 27Knoppers,26 and George Annas, to explore these issues, with a particular
focus on human cloning. In a lecture entitled What If Anything Is Wrong
with Cloning a Human Being? ,28 Dr. Caplan allays many common fears
about human cloning, providing an expert's perspective on the different
technologies, uses, benefits and risks, as well as the limitations and
foreseeable consequences of the technology. In the end, he favors
therapeutic but rejects reproductive cloning. In her lecture, Human Dignity:
In Danger of Banality? (The Case of Cloning),29 Professor Knoppers
proposes a human rights model based on the concept of human dignity. She
recommends that the international regime balance any current ban on
cloning against the need to continue research and proposes a more multi-
faceted, complex systems approach to the internalization of human dignity
as a fundamental norm. In the final lecture entitled Arbitrage, Bioethics,
and Cloning: the ABC's of Gestating a United Nations Cloning Convention,
30 Professor George Annas, along with Rosario M. Isasi, examines recent
attempts to create a U.N. Convention to ban human cloning and observes
that mainstream researchers are engaged in regulatory arbitrage: the
infertility industry still has not set any limits as to where U.S. researchers
can go to "evade our almost nonexistent legal and ethical constraints.' In
order to solve the arbitrage problem, he argues for an international cloning
treaty that would recognize cloning as an "offense against humanity."
Notwithstanding the breadth, complexity, or novelty of international legal
arbitrage as an area of sustained scholarly attention, this volume thus takes
an important step forward in recording the observations of these leading
voices on the global regulation of controversial technologies.
26 Bartha-Maria Knoppers, Canada Research Chair in Law and Medicine, is Professor at
the Facultd de droit, Universit6 de Montrdal and Senior Researcher at the Centre for Public
Law (C.R.D.P.). She is a graduate of McMaster University (B.A.), University of Alberta
(M.A.), McGill University (LL.B., B.C.L.), Cambridge University, U.K., (D.L.S.), Sorbonne
(Paris I) (PhD.)
27 George J. Annas is the Edward R. Utley Professor and Chair of the Department of
Health Law, Bioethics & Human Rights of Boston University School of Public Health, and
Professor in the Boston University School of Medicine and School of Law. He is the
cofounder of Global Lawyers and Physicians, a transnational professional association of
lawyers and physicians working together to promote human rights and health. He has
degrees from Harvard College (A.B.), Harvard Law School (J.D.) and Harvard School of
Public Health (M.P.H.).
28 Arthur L. Caplan, What if Anything is Wrong with Human Cloning?, 35 CASE J. INT'L L
369(2003).
29 Bartha-Maria Knoppers, Human Dignity: In Danger of Banality? (THE CASE
OF CLONING), 35 CASE J. INT'L L 385 (2003).
30 George J. Annas & Rosario M. Isasi, Arbitrage, Bioethics, and Cloning:The
ABCs of Gestating a United Nations Cloning Convention, 35 CASE J. INT'L L 397
(2003).
31 Id. at 398.
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